Rituximab in systemic sclerosis: A protocol for systematic review
Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regardin...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2019-09, Vol.98 (38), p.e17110-e17110 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e17110 |
|---|---|
| container_issue | 38 |
| container_start_page | e17110 |
| container_title | Medicine (Baltimore) |
| container_volume | 98 |
| creator | Caldas, Marina Maria Vieira de Figueiredo Neto, Francisco Alves Bezerra Azevedo, Kesley Pablo Morais de Pimenta, Isac Davidson Santiago Fernandes Oliveira, Ana Katherine Da Silveira Gonçalves De Piuvezam, Grasiela |
| description | Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc.
This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results.
In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX.
The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researches.
CRD42019132018. |
| doi_str_mv | 10.1097/MD.0000000000017110 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6756608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2299771322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3558-d98e1743f5c584b52f9e3abdf29500be02d59b1ae3f8865f2c4654de80c0a23d3</originalsourceid><addsrcrecordid>eNpdkE1P3DAQhi3UCraUX4CEcuwldPwV2z1UWkE_kEBIqD1bjjPpunjXWzthy79v6C60MJc5zDPPjF5CjimcUjDq_dX5KfwrqiiFPTKjkje1NI14RWYATNbKKHFA3pTyc4K4YmKfHHAqG2WEnpH5TRjG32Hp2iqsqnJfBlwGXxUfMacSyodqXq1zGpJPsepT3iFumKCMdwE3b8nr3sWCR7t-SL5__vTt7Gt9ef3l4mx-WXsupa47o5EqwXvppRatZL1B7tquZ0YCtAisk6alDnmvdSN75kUjRYcaPDjGO35IPm6967FdYudxNWQX7TpPz-d7m1ywzyersLA_0p1tlGwa0JPg3U6Q068Ry2CXoXiM0a0wjcUyZoxSlDM2oXyL-imEkrF_OkPBPoRvr87ty_CnrZP_P3zaeUx7AsQW2KQ4YC63cdxgtgt0cVj89UllWM2AGjAMoH5Qa_4HfqeQJA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2299771322</pqid></control><display><type>article</type><title>Rituximab in systemic sclerosis: A protocol for systematic review</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Caldas, Marina Maria Vieira de Figueiredo ; Neto, Francisco Alves Bezerra ; Azevedo, Kesley Pablo Morais de ; Pimenta, Isac Davidson Santiago Fernandes ; Oliveira, Ana Katherine Da Silveira Gonçalves De ; Piuvezam, Grasiela</creator><creatorcontrib>Caldas, Marina Maria Vieira de Figueiredo ; Neto, Francisco Alves Bezerra ; Azevedo, Kesley Pablo Morais de ; Pimenta, Isac Davidson Santiago Fernandes ; Oliveira, Ana Katherine Da Silveira Gonçalves De ; Piuvezam, Grasiela</creatorcontrib><description>Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc.
This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results.
In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX.
The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researches.
CRD42019132018.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000017110</identifier><identifier>PMID: 31567948</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - therapeutic use ; Clinical Protocols ; Humans ; Rituximab - administration & dosage ; Rituximab - therapeutic use ; Scleroderma, Systemic - drug therapy ; Study Protocol Systematic Review ; Systematic Reviews as Topic</subject><ispartof>Medicine (Baltimore), 2019-09, Vol.98 (38), p.e17110-e17110</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3558-d98e1743f5c584b52f9e3abdf29500be02d59b1ae3f8865f2c4654de80c0a23d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756608/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756608/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31567948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Caldas, Marina Maria Vieira de Figueiredo</creatorcontrib><creatorcontrib>Neto, Francisco Alves Bezerra</creatorcontrib><creatorcontrib>Azevedo, Kesley Pablo Morais de</creatorcontrib><creatorcontrib>Pimenta, Isac Davidson Santiago Fernandes</creatorcontrib><creatorcontrib>Oliveira, Ana Katherine Da Silveira Gonçalves De</creatorcontrib><creatorcontrib>Piuvezam, Grasiela</creatorcontrib><title>Rituximab in systemic sclerosis: A protocol for systematic review</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc.
This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results.
In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX.
The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researches.
CRD42019132018.</description><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Clinical Protocols</subject><subject>Humans</subject><subject>Rituximab - administration & dosage</subject><subject>Rituximab - therapeutic use</subject><subject>Scleroderma, Systemic - drug therapy</subject><subject>Study Protocol Systematic Review</subject><subject>Systematic Reviews as Topic</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1P3DAQhi3UCraUX4CEcuwldPwV2z1UWkE_kEBIqD1bjjPpunjXWzthy79v6C60MJc5zDPPjF5CjimcUjDq_dX5KfwrqiiFPTKjkje1NI14RWYATNbKKHFA3pTyc4K4YmKfHHAqG2WEnpH5TRjG32Hp2iqsqnJfBlwGXxUfMacSyodqXq1zGpJPsepT3iFumKCMdwE3b8nr3sWCR7t-SL5__vTt7Gt9ef3l4mx-WXsupa47o5EqwXvppRatZL1B7tquZ0YCtAisk6alDnmvdSN75kUjRYcaPDjGO35IPm6967FdYudxNWQX7TpPz-d7m1ywzyersLA_0p1tlGwa0JPg3U6Q068Ry2CXoXiM0a0wjcUyZoxSlDM2oXyL-imEkrF_OkPBPoRvr87ty_CnrZP_P3zaeUx7AsQW2KQ4YC63cdxgtgt0cVj89UllWM2AGjAMoH5Qa_4HfqeQJA</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Caldas, Marina Maria Vieira de Figueiredo</creator><creator>Neto, Francisco Alves Bezerra</creator><creator>Azevedo, Kesley Pablo Morais de</creator><creator>Pimenta, Isac Davidson Santiago Fernandes</creator><creator>Oliveira, Ana Katherine Da Silveira Gonçalves De</creator><creator>Piuvezam, Grasiela</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190901</creationdate><title>Rituximab in systemic sclerosis: A protocol for systematic review</title><author>Caldas, Marina Maria Vieira de Figueiredo ; Neto, Francisco Alves Bezerra ; Azevedo, Kesley Pablo Morais de ; Pimenta, Isac Davidson Santiago Fernandes ; Oliveira, Ana Katherine Da Silveira Gonçalves De ; Piuvezam, Grasiela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3558-d98e1743f5c584b52f9e3abdf29500be02d59b1ae3f8865f2c4654de80c0a23d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Clinical Protocols</topic><topic>Humans</topic><topic>Rituximab - administration & dosage</topic><topic>Rituximab - therapeutic use</topic><topic>Scleroderma, Systemic - drug therapy</topic><topic>Study Protocol Systematic Review</topic><topic>Systematic Reviews as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Caldas, Marina Maria Vieira de Figueiredo</creatorcontrib><creatorcontrib>Neto, Francisco Alves Bezerra</creatorcontrib><creatorcontrib>Azevedo, Kesley Pablo Morais de</creatorcontrib><creatorcontrib>Pimenta, Isac Davidson Santiago Fernandes</creatorcontrib><creatorcontrib>Oliveira, Ana Katherine Da Silveira Gonçalves De</creatorcontrib><creatorcontrib>Piuvezam, Grasiela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Caldas, Marina Maria Vieira de Figueiredo</au><au>Neto, Francisco Alves Bezerra</au><au>Azevedo, Kesley Pablo Morais de</au><au>Pimenta, Isac Davidson Santiago Fernandes</au><au>Oliveira, Ana Katherine Da Silveira Gonçalves De</au><au>Piuvezam, Grasiela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rituximab in systemic sclerosis: A protocol for systematic review</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>98</volume><issue>38</issue><spage>e17110</spage><epage>e17110</epage><pages>e17110-e17110</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Systemic sclerosis (SSc) is a clinically complex and challenging disease, the most frequent complication of which is interstitial lung disease, which leads to a worse prognosis. In this situation, cyclophosphamide is considered the criterion standard for treatment, despite the controversies regarding its efficacy and toxicity. However, studies using rituximab (RTX) have shown that this drug may be a promising therapeutic option. The objective is to describe a protocol of a systematic review (SR) that analyzes the scientific evidence on the effects of RTX on SSc.
This protocol is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. The databases to be searched are PubMed, Scopus, SciELO, LILACS, ScienceDirect, Web of Science, COCHRANE, WHOLIS, PAHO, and EMBASE. The studies that would be included in SR are clinical trials that evaluate the use of RTX in patients with SSc who meet the classification criteria for the disease according to American College of Rheumatology and European League Against Rheumatism (2013) and/or LeRoy criteria will be included in the SR. The data to be extracted are related to the characteristics of the studies: authors, year of publication, study location, type of study, sample size and age, patient characteristics, duration of intervention, therapeutic scheme, follow-up time, main variables, and main results.
In our study, we hope to find articles presenting new evidence supporting treatment of SSc with RTX.
The SR will present results of scientific evidence for the effects of RTX in SSc. We hope that the results could strengthen clinical decisions for the best treatment of SSc and guide future researches.
CRD42019132018.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>31567948</pmid><doi>10.1097/MD.0000000000017110</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2019-09, Vol.98 (38), p.e17110-e17110 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6756608 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antirheumatic Agents - administration & dosage Antirheumatic Agents - therapeutic use Clinical Protocols Humans Rituximab - administration & dosage Rituximab - therapeutic use Scleroderma, Systemic - drug therapy Study Protocol Systematic Review Systematic Reviews as Topic |
| title | Rituximab in systemic sclerosis: A protocol for systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A45%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rituximab%20in%20systemic%20sclerosis:%20A%20protocol%20for%20systematic%20review&rft.jtitle=Medicine%20(Baltimore)&rft.au=Caldas,%20Marina%20Maria%20Vieira%20de%20Figueiredo&rft.date=2019-09-01&rft.volume=98&rft.issue=38&rft.spage=e17110&rft.epage=e17110&rft.pages=e17110-e17110&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000017110&rft_dat=%3Cproquest_pubme%3E2299771322%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2299771322&rft_id=info:pmid/31567948&rfr_iscdi=true |